Phase 4 N=145 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
Asthma
Primary: Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 32 — -1.45 Scores on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=182 Staying Active With Arthritis: RCT of Physical Activity for Older Adults With Osteoarthritis and Hypertension
Osteoarthritis, Knee · Hypertension
Primary: Performance of Lower Extremity Exercise at 25 Weeks — 46.84; 1.90 repetitions x sets/week — p=<.0001
Phase 2 N=399 N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
Radiocontrast Nephropathy
Primary: Number of Participants With Contrast-induced Nephropathy — 14; 12 Participants — p=>0.5
Phase 2 N=88 Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Number of Phase I Patients Receiving 60mg or 80mg BKM120 Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 3 Participants
N/A N=41 Asthma Controller Adherence After Hospitalization
Asthma
Primary: Comparison of Number and Percentage of Patients That Use Monitoring Device Over 30 Days (Feasibility) — 15; 17 Participants
N/A N=1,765 Physical Activity and Nutrition Intervention in Afterschool Programs
Childhood Obesity
Primary: Change in Percentage of Children Meeting Physical Activity Policy — 35.9; 29.0; 44.2; 29.3 Percent children achieving MVPA standard — p=0.008
N/A N=83 Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma
Liver Cancer
Primary: 2 Year Local Control Rate — 94.4 percentage of participants
Phase 3 N=56 Study of Mepolizumab Safety Syringe in Asthmatics
Asthma
Primary: Percentage of Participants With Successful Self-administration of Their Observed Third Dose at Week 8 — 100 Percentage of participants
Phase 2 N=51 Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements
Edematous · Synovitis · Foreign Body Reaction
Primary: Pain Visual Analog Scale (VAS) — 57; 46.8; 39.7; 39.1 units on a scale — p=0.0063
Phase 2 N=227 Investigating the Effect of Vortioxetine in Adult ADHD Patients
Attention Deficit Hyperactivity Disorder
Primary: Change in ADHD Investigator Symptom Rating Scale (AISRS) Total Score — -12.4; -12.8; -11.6; -4.1 units on a scale — p=0.9723
Phase 2 N=13 Early FMT for C.Difficile
Clostridium Difficile
Primary: Clinical Remission Rates — 3; 2 Participants
N/A N=5 Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Alzheimer's Disease · Depression
Primary: Changes in Dose Response Using the Modified Alzheimer's Disease (AD) Cooperative Study-Clinical Global Impression of Change. — 2; 0; 1; 2 Participants
N/A N=6,443 Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation
Atrial Fibrillation
Primary: Frequency (Percentage) of Participants With Adverse Drug Reactions — 28.2 Percentage of participants
Phase 3 N=201 Chronic Kidney Disease Antidepressant Sertraline Trial
Chronic Kidney Disease · Depression
Primary: Change From Baseline to Exit in Depression Symptom Severity as Measured by the QIDS-C-16 Score. — -4.1; -4.2 units on a scale — p=0.82
N/A N=88 Hemostasis in Open Acetabulum and Pelvic Ring Surgery Using Tranexamic Acid
Acetabulum Fractures
Primary: Intra-operative Blood Loss — 727.6; 560.1 Milliliters